Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPE-NaF: Icosapent Ethyl on High-Risk Coronary Plaques
NCT07762755Phase 4Not yet recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 4 trial of omega-3-acid triglycerides in coronary artery disease (CAD), hyperlipidemia, hypertriglyceridemia, Coronary atherosclerosis (CAD), sponsored by National Center for Cardiovascular Disease. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
omega-3-acid triglycerides
03
Conditions
coronary artery disease (CAD)hyperlipidemiahypertriglyceridemiaCoronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT07762755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762755.